Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Bengt Winblad(Karolinska Institutet), Niels Andreasen(Karolinska Institutet), Lennart Minthon, Annette Floesser(Novartis (Switzerland)), Georges Imbert(Novartis (Switzerland)), Thomas Dumortier(Novartis (Switzerland)), R. P. Maguire(Novartis Institutes for BioMedical Research), Kaj Blennow(University of Gothenburg), Joens Lundmark(Novartis (Sweden)), Matthias Staufenbiel(Novartis (Switzerland)), Jean‐Marc Orgogozo(Université de Bordeaux), Ana Graf(Novartis (Switzerland))
Cited by 302
Abstract
Related Papers
No related papers found
Powered by citation graph analysis